Skip to main content

Brexucabtagene Autoleucel

(brek-suh-KAB-tuh-jeen aw-toh-LOO-sel)

This page contains brief information about brexucabtagene autoleucel and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Tecartus
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Brexucabtagene autoleucel is approved to treat adults with:

This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that brexucabtagene autoleucel provides a clinical benefit in these patients.

Brexucabtagene autoleucel is only available as part of a special program called Tecartus REMS (Risk Evaluation and Mitigation Strategies).

Brexucabtagene autoleucel is also being studied in the treatment of other types of cancer.

More About Brexucabtagene Autoleucel

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

CAR T-Cell Therapy Approved by FDA for Mantle Cell Lymphoma

Targeted Cancer Therapies

T-cell Transfer Therapy

CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers

Clinical Trials Accepting Patients

Find Clinical Trials for Brexucabtagene Autoleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: